IL6 and neoplasm: Therapies targeting the desmoplastic stroma and/or inflammatory factors such as IL-6, COX-2, CXCL8, and TGFβ might have the potential to manipulate the tumor microenvironment to benefit attraction of DCs and differentiation of monocytes into functional DCs which could affect the clinical outcome for the PDAC patients.